PDE4A and asthma: To enhance this metabolic pathway, the intracellular break down of cAMP may be blocked by inhibitors of PDEs, such as the PDE4 inhibitor rolipram which leads to an enhanced efficacy of Treg mediated suppression in vitro and also in vivo, as recently demonstrated in an asthma model [23].